A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia-Reference-Cited by-同舟云学术

A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia

Published:2022-01 Issue:1 Volume:8 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Vivash Lucy¹²³⁴,Malpas Charles B.¹²³⁵,Meletis Christian³⁴,Gollant Meghan¹,Eratne Dhamidhu⁶⁷⁸,Li Qiao‐Xin⁸,McDonald Stuart¹⁹,O'Brien William T.¹,Brodtmann Amy³¹⁰,Darby David²³¹⁰,Kyndt Christopher³,Walterfang Mark⁶⁷,Hovens Christopher M.¹¹,Velakoulis Dennis⁶⁷,O'Brien Terence J.¹²³⁴

Affiliation:

1. Department of Neurosciences Central Clinical School Monash University Melbourne Australia

2. Department of Neurology Alfred Hospital Melbourne Australia

3. Department of Neurology Royal Melbourne Hospital Parkville Australia

4. Department of Medicine and Radiology The University of Melbourne Parkville Australia

5. Melbourne School of Psychological Sciences The Royal Melbourne Hospital The University of Melbourne Parkville Australia

6. Neuropsychiatry Royal Melbourne Hospital Parkville Australia

7. Melbourne Neuropsychiatry Centre University of Melbourne and North‐Western Mental Health Parkville Australia

8. The National Dementia Diagnostics Laboratory The Florey Institute, The University of Melbourne Parkville Australia

9. Department of Physiology Anatomy and Microbiology La Trobe University Bundoora Australia

10. Florey Institute of Neuroscience and Mental Health Melbourne

11. Department of Surgery Royal Melbourne Hospital, University of Melbourne Melbourne Australia

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12299

Reference27 articles.

1. The prevalence of frontotemporal dementia

2. Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease

3. Protein Phosphatase 2A Is the Major Enzyme in Brain that Dephosphorylates τ Protein Phosphorylated by Proline-Directed Protein Kinases or Cyclic AMP-Dependent Protein Kinase

4. Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau

5. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer’s disease model

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer’s Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy;Neurochemical Research;2024-06-06

2. Progressive Supranuclear Palsy Syndrome: An Overview;IBRO Neuroscience Reports;2024-06

3. Altering phosphorylation in cancer through PP2A modifiers;Cancer Cell International;2024-01-06

4. Tau-targeting therapies for Alzheimer disease: current status and future directions;Nature Reviews Neurology;2023-10-24

5. Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol;BMJ Open;2023-10